Oramed Pharmaceuticals Inc (ORMP) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Oramed Pharmaceuticals Inc  (NASDAQ: ORMP)


Oramed Pharmaceuticals Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Oramed Pharmaceuticals Inc's ROI in the second quarter of 2026?
Oramed Pharmaceuticals Inc achieved a return on average invested assets (ROI) of 69.44 % in its second quarter of 2026, this is above ORMP's average return on investment of 27.75%.
Oramed Pharmaceuticals Inc invested over the 12 months ending in its second quarter of 2026 $252 million

ROI has improved compared to 54.86% in the first quarter of 2026, due to net income growth.

Within the Healthcare sector 16 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Jun 30 2026 quarter, so far to 79, from total ROI ranking in the first quarter of 2026 at 88.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM 70.54 % 30.75 % 9.25 % -4.09 % -10.69 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 358 238 210 201 153
Return On Investment (TTM) 69.44 % 54.86 % 36.45 % 27.52 % -16.38 %
ORMP's Overall Ranking # 79 # 88 # 187 # 2640 #
Seq. Investment Change TTM 25.63 % 14.13 % 10.22 % 7.92 % -3.69 %
Seq. Net Income Change TTM 59.01 % 71.78 % 45.99 % - -
Net Income (TTM) in Millions 175 110 64 44 -24

ORMP Company Profile >> Back to ORMP Roi Comparisons >> See Annual ORMP Return On Investment



Return On Investment ORMP's Ranking
Within: No.
Industry # 7
Sector # 17
Overall # 79

Return On Investment Statistics
High Average Low
74.57 %
27.75 %
-17.99 %
(Aug 31 2013)   (Mar 31 2025)







Financial Statements
Oramed Pharmaceuticals Inc's II. Quarter Investments $ 358 Millions ORMP's Balance sheet
Oramed Pharmaceuticals Inc's II. Quarter Income $ 78 Millions Quarterly ORMP's Income Statement
ORMP's Income by Division See ORMP's Income by Division


ORMP Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Aug 31 2021)
2021
Total Investments in Millions 210 144 166 182 159
Y / Y Investment Growth 45.09 % -12.98 % -8.67 % 14.26 % 296.97 %
Net Income in Millions 64 -19 6 -38 -23
Y / Y Net Income Growth - - - - -
Annual Return On Investment 30.55 % -13.2 % 3.33 % -20.78 % -14.45 %


Annual Roi Comment
In the fiscal year 2025 ROI improved to 30.55 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
ORMP's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for ORMP's Competitors
Subscribers only: Roi for Oramed Pharmaceuticals Inc's Suppliers
Subscribers only: Return On Investment for ORMP's Customers

Other Ratios
ORMP's Roa ORMP's Inventory Turnover Ratio ORMP's Growth Rates ORMP's Dividend Statistics
ORMP's Profitability Ratios ORMP's Asset Turnover Ratio ORMP's Dividend Growth
ORMP's Roe ORMP's Valuation Ratios ORMP's Financial Strength Ratios ORMP's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI
Sanuwave Health Inc   167.92 %
Vor Biopharma Inc   162.71 %
Capforce Inc   161.42 %
Kyntra Bio Inc   157.74 %
Silexion Therapeutics Corp  127.60 %
Quince Therapeutics Inc   112.49 %
Pulmatrix Inc   108.83 %
Interpace Biosciences Inc   100.71 %
Arbutus Biopharma Corp  99.18 %
Rigel Pharmaceuticals Inc  89.00 %
Oncotelic Therapeutics Inc   87.35 %
Actinium Pharmaceuticals Inc  84.38 %
Exelixis Inc   82.05 %
Lensar Inc   75.31 %
Ironwood Pharmaceuticals inc   70.54 %
Oramed Pharmaceuticals Inc  68.90 %
Indivior Pharmaceuticals Inc   68.79 %
Rallybio Corporation  68.28 %
Fortress Biotech Inc   68.27 %
Earth Science Tech Inc   64.38 %
Meiragtx Holdings Plc  55.83 %
Elite Pharmaceuticals Inc   53.48 %
Idexx Laboratories Inc  51.80 %
Aurinia Pharmaceuticals Inc   50.35 %
Qhslab Inc   48.94 %
Q32 Bio Inc   47.43 %
Vaxart Inc   46.17 %
Liquidia Corporation  42.09 %
Tg Therapeutics Inc   39.26 %
Medpace Holdings Inc   35.54 %

Date modified: 2026-08-14T05:15:54+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.